Press Releases

Press Releases

Date Title and Summary Additional Formats
Toggle Summary NeuroMetrix, Inc. Announces Date for First Quarter 2023 Financial Results Conference Call
WOBURN, Mass. , April 28, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2023 first quarter financial results before the opening of the market on May 3, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time on May 3, 2023 to
View HTML
Toggle Summary NeuroMetrix to Exhibit Quell® Fibromyalgia and Present New Clinical Data at the American Academy of Pain Medicine 2023 Annual Meeting
WOBURN, Mass. , March 21, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will exhibit Quell Fibromyalgia at the American Academy of Pain Medicine 39 th Annual Meeting on March 23 - 26 in Ft. Lauderdale, FL. In addition, two scientific posters reporting new data on the use of Quell in
View HTML
Toggle Summary NeuroMetrix Reports Q4 and Full Year 2022 Financial Results
WOBURN, Mass. , Feb. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and full year ended December 31, 2022 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on individuals and
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Fourth Quarter and Full Year 2022 Financial Results Conference Call
WOBURN, Mass. , Feb. 16, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 fourth quarter and year end financial results before the opening of the market on February 23, 2023 . The Company will host a conference call at 8:00 a.m., Eastern Time
View HTML
Toggle Summary NeuroMetrix® Announces Launch of DPNCheck® 2.0, its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy
Point-of-care technology helps healthcare providers rapidly identify at-risk patients WOBURN, Mass. , Jan. 23, 2023 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced the commercial availability of DPNCheck 2.0, the Company's latest point-of-care device that leverages
View HTML
Toggle Summary NeuroMetrix to Introduce Quell® Fibromyalgia at the American College of Rheumatology 2022 Annual Meeting
WOBURN, Mass. , Nov. 08, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) will introduce Quell Fibromyalgia at the American College of Rheumatology Annual Meeting, ACR Convergence 2022, on November 12 – 14 in Philadelphia, Pennsylvania . Quell Fibromyalgia is a wearable neuromodulation
View HTML
Toggle Summary NeuroMetrix Announces Strategic Launch of Quell Fibromyalgia
WOBURN, Mass. , Nov. 03, 2022 (GLOBE NEWSWIRE) --  NeuroMetrix, Inc. (Nasdaq: NURO) today announced the strategic launch of its Quell ® Fibromyalgia device through the Pathfinder Program. Quell Fibromyalgia is the first and only medical device authorized by the U.S.
View HTML
Toggle Summary NeuroMetrix Reports Q3 2022 Financial Results
WOBURN, Mass. , Oct. 20, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter and nine-month period ended September 30, 2022 . The Company's mission is to reduce the impact of neurological disorders and pain syndromes on
View HTML
Toggle Summary NeuroMetrix, Inc. Announces Date for Third Quarter 2022 Financial Results Conference Call
WOBURN, Mass. , Oct. 12, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) announced today that it plans to issue its 2022 third quarter financial results before the opening of the market on Oct 20, 2022 . The Company will host a conference call at 8:00 a.m., Eastern Time on Oct 20, 2022 to
View HTML
Toggle Summary NeuroMetrix Names Jonathan Breck Harmel as National Director of Sales for its Emerging Prescription Neurotherapeutics Business
WOBURN, Mass. , Sept. 01, 2022 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today announced that it has appointed Jonathan "Breck" Harmel as National Director of Sales, Neuromodulation. Mr. Harmel will be responsible for leading the sales organization for the Company's prescription wearable
View HTML